Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They are signals.

Sanofi’s decision not to renew Paul Hudson’s mandate as CEO marks a structural shift — not just for the company, but for how global pharma boards now evaluate performance.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

Free Membership Required

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Topics

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

Related Articles

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Company

Headlines

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

Newsletter